{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-116023","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.717414+00:00","generated_at":"2026-05-22T05:09:08.983076+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcellx Q1 net loss $62.3M; cash $565M; iMMagine-3 adds MRD endpoint","bullets":["Net loss of $62.3M vs $7.2M in Q1 2024; collaboration revenue down to $8.1M from $39.3M.","Cash and equivalents $565.2M; funding expected into 2028.","iMMagine-1 data (117 patients) accepted for oral presentation at EHA June 14, 2025.","iMMagine-3 study updated to include MRD negativity as dual primary endpoint alongside PFS.","Appointed Andrew Galligan and Kristin Myers to Board; anito-cel launch planned for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-116023","json":"https://secwatch.observer/filing/0001193125-25-116023.json","markdown":"https://secwatch.observer/filing/0001193125-25-116023.md","text":"https://secwatch.observer/filing/0001193125-25-116023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/0001193125-25-116023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/d916048d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:09:08.983076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}